Ad Header



The Pulse of the Pharmaceutical Industry

Abbott strikes deals with heart valve replacement companies

Written by: | | Dated: Thursday, July 30th, 2015

Abbott Laboratories (ABT.N) on Thursday said it would buy a small private company and has invested in another, with an option to buy, as it places bets on the future growth potential of minimally invasive systems to replace diseased heart valves.

Abbott said it has agreed to acquire the equity in Minnesota-based Tendyne Holdings Inc that it does not already own for $250 million plus future payments tied to regulatory milestones.

In a separate transaction in which financial details were not disclosed, Abbott said it has provided capital and secured an option to purchase California-based Cephea Valve Technologies.

Both private companies are developing systems to replace diseased mitral valves in the heart while sparing patients traditional chest-cracking open-heart surgery.

Neither deal is expected to alter Abbott’s 2015 earnings forecast, the company said.



(Reporting by Bill Berkrot; Editing by James Dalgleish)

Source: Reuters

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom